Greatest additional benefit was seen in the second decade after diagnosis. Findings are directly relevant to women taking tamoxifen. Women on other ER-positive breast cancer endocrine treatments may benefit. SAN ANTONIO — Ten years of adjuvant treatment with tamoxifen provided women with estrogen...
Posted to
News
by
AACR News
on
Wed, Dec 5 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Cancer, Media Materials, AACR, American Association for Cancer Research, CTRC-AACR San Antonio Breast Cancer Symposium, CTRC, press conference, tamoxifen, ER-positive breast cancer, San Antonio Breast Cancer Symposium, SABCS, Baylor College of Medicine, ATLAS trial, Dr. Christina Davies
HDAC inhibitor with tamoxifen treatment reduced tumor cell resistance in estrogen receptor-positive breast cancer. Critical pathway by which tumors become tamoxifen resistant identified. Early introduction of HDAC inhibitor with tamoxifen is key. SAN FRANCISCO — Researchers have shown how estrogen...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Breast Cancer, Conference, Cancer, Media Materials, AACR, American Association for Cancer Research, meeting, National Cancer Institute, NCI, estrogen receptor-positive breast cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, HDAC inhibitor, tamoxifen, ER-positive breast cancer, AKT, Dr. Pamela N. Munster